Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Neoadjuvant Chemoradiotherapy

Neoadjuvant Chemoradiotherapy

Neoadjuvant chemoradiotherapy is a combination of chemotherapy and radiotherapy administered before the primary treatment, typically surgery, for certain types of cancers.
This approach aims to shrink the tumor, improve the chances of successful surgery, and potentially enhance long-term outcomes.
The goal is to optimize the treatment protocol by identifying the most effective strategies and products through data-driven decision making, using tools that facilitate research reproducibility and accuracy.
PubCompare.ai offers AI-driven solutions to help researchers quickly locate and compare the latest neoadjuvant chemoradiotherapy protocols from scientific literature, preprints, and patents, enabling them to make informed decisions and experince the power of data-driven research.

Most cited protocols related to «Neoadjuvant Chemoradiotherapy»

1
Neoadjuvant Therapy for Pancreatic Cancer
Cited 5 times
After obtaining approval from the institutional review board, we retrospectively analyzed 398 patients who had undergone pancreaticoduodenectomy (PD), after neoadjuvant therapy for PDAC at University of Texas MD Anderson Cancer Center between January 1999 to December 2012. They were identified from a database that is prospectively maintained by the Department of Surgical Oncology. A waiver of consent was granted for the use of their specimen information for research. We excluded patients who had undergone distal pancreatectomy and those who had undergone PD and neoadjuvant therapy for other neoplasms. The clinical and follow-up information such as date of diagnosis, date and site of recurrence, or date and cause of death, when applicable, was verified by reviewing patients’ medical records and the U.S. Social Security Index. Disease recurrence or metastasis was determined on the basis of radiographic and clinical suspicion, as often, biopsy confirmation had not been obtained.
Our study population consisted of 222 male and 176 female patients, with ages ranging from 34.5 years to 85.4 years (median age, 64.1 years). Seventy-four patients (18.6%) had undergone neoadjuvant fluoropyrimidine-based chemoradiation therapy (group 1), 101 (25.4%) neoadjuvant gemcitabine-based chemoradiation therapy (group 2), 102 (25.6%) systemic chemotherapy followed by gemcitabine-based chemoradiation therapy (group 3), 103 (25.9%) systemic chemotherapy followed by fluoropyrimidine-based chemoradiation therapy (group 4), and 18 (4.5%) neoadjuvant systemic chemotherapy alone (group 5, Table 1).
Chatterjee D., Katz M.H., Foo W.C., Sundar M., Wang H., Varadhachary G.R., Wolff R.A., Lee J.E., Maitra A., Fleming J.B., Rashid A, & Wang H. (2017). Prognostic Significance of New AJCC Tumor Stage in Patients with Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Therapy. The American journal of surgical pathology, 41(8), 1097-1104.
Publication 2017
Anophthalmia with pulmonary hypoplasia Biopsy Chemoradiotherapy Diagnosis Ethics Committees, Research Gemcitabine Males Malignant Neoplasms Neoadjuvant Chemoradiotherapy Neoadjuvant Chemotherapy Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Pancreatectomy Pancreaticoduodenectomy Patients Pharmacotherapy Recurrence Therapeutics Woman X-Rays, Diagnostic
2
Neoadjuvant Chemoradiation Therapy for PDAC
Cited 5 times
Our study population consisted of 223 patients with histologically confirmed diagnosis of PDAC who received neoadjuvant chemoradiation therapy and subsequently underwent pancreaticoduodenectomy (PD). There were 130 male and 93 female patients with age ranging from 38.9 to 85.4 years (median age: 62.9 years). Thirty-nine patients (17.5%) received neoadjuvant fluoropyrimidine-based chemoradiation (group 1), 69 (30.9%) received neoadjuvant gemcitabine-based chemoradiation (group 2), 75 (33.6%) received systemic chemotherapy followed by gemcitabine-based chemoradiation (group 3), 35 (15.7%) received systemic chemotherapy followed by fluoropyrimidine-based chemoradiation (group 4) and the remaining five patients (2.3%) received neoadjuvant systemic chemotherapy alone (group 5). One hundred and forty-four (64.6%) of these patients (groups 2 and 3) were treated on previously published protocols.8 (link), 9 (link) Upon completion of neoadjuvant therapy, all patients underwent restaging evaluation and PD was performed only in patients with resectable disease without disease progression or metastasis, and who had no contraindications to major abdominal surgery. Patients who underwent distal pancreatectomy for PDAC and those who underwent PD for other types of pancreatic tumors were excluded.
The clinical and follow-up information through December 2009 was extracted from a prospectively maintained database at the Department of Surgical Oncology and verified by reviewing patient medical records and the U.S. Social Security Index. The first site or sites of disease recurrence were classified as either local/regional or distant recurrence based on the computer tomography (CT) scan. Biopsy confirmation of metastasis was rarely performed. Local/regional recurrence was defined as recurrence in the region of the pancreatic bed, root of mesentery, soft tissues or lymph nodes adjacent to the pancreatic bed. Distant metastasis was defined as radiographic evidence of tumor spread to the liver, lungs, peritoneal cavity (including ascites), or other distant organs. This study was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center.
Chatterjee D., Katz M.H., Rashid A., Varadhachary G.R., Wolff R.A., Wang H., Lee J.E., Pisters P.W., Vauthey J.N., Crane C., Gomez H.F., Abbruzzese J.L., Fleming J.B, & Wang H. (2011). Histologic Grading the Extent of Residual Carcinoma Following Neoadjuvant Chemoradiation in Pancreatic Ductal Adenocarcinoma: A Predictor for Patient Outcome. Cancer, 118(12), 3182-3190.
Publication 2011
Abdomen Anophthalmia with pulmonary hypoplasia Ascites Biopsy Chemoradiotherapy Diagnosis Disease Progression Ethics Committees, Research Gemcitabine Liver Lung Males Malignant Neoplasms Mesentery Neoadjuvant Chemoradiotherapy Neoadjuvant Chemotherapy Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Nodes, Lymph Pancreas Pancreatectomy Pancreatic Neoplasm Pancreaticoduodenectomy Patients Peritoneal Cavity Pharmacotherapy Radionuclide Imaging Recurrence Tissues Tomography Tooth Root Woman X-Rays, Diagnostic
3
Retrospective Analysis of Colorectal Cancer
Cited 3 times
In this retrospective analysis, we used data from the SEER linked database. The SEER Program of the National Cancer Institute is an authoritative source of information on cancer incidence and survival in the United States (U.S.) that is updated annually. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6 percent of the U.S. population. Data from SEER was used to identify patients with CRC diagnosed between 2004 and 2013. Among the 90,529 patients diagnosed with CRC between these years, patients with the following characteristics were included: (a) the patients were over 18 years old; (b) CRC was the first and only malignant tumor; (c) surgical resection was performed; (d) there was complete staging information; and (e) no neoadjuvant chemoradiation was used in treatment. The final study sample contained 56,747 patients.
Pei J.P., Zhang C.D., Fan Y.C, & Dai D.Q. (2019). Comparison of Different Lymph Node Staging Systems in Patients With Resectable Colorectal Cancer. Frontiers in Oncology, 8, 671.
Publication 2018
Malignant Neoplasms Neoadjuvant Chemoradiotherapy Operative Surgical Procedures Patients
4
Neoadjuvant Therapy and Outcomes in PDAC
Cited 3 times
The study was approved by the Institutional Review Board at the University of Texas M.D. Anderson Cancer Center (MD Anderson). One hundred sixty-seven consecutive patients were included in this study from our prospective maintained, institutional pancreatic tumor database. Our study population consists of 84 male and 83 female patients with age ranging from 34 to 85 years at the time of surgery (median age, 65 years). All patients had histologically confirmed PDAC, completed neoadjuvant therapies and underwent PD at our institution between 2008 and 2012. We excluded from analysis the patients who underwent distal pancreatectomy for recurrent PDAC (n=2), periampullary adenocarcinoma (n=3), invasive adenocarcinoma arising in an intraductal papillary mucinous neoplasm (n=2), and adenocarcinoma arising in the distal bile duct (n=3).
Twenty-nine patients (17.4%) received neoadjuvant fluoropyrimidine based chemoradiation (TX1), 30 patients (18.0%) received neoadjuvant gemcitabine-based chemoradiation (TX2), 22 patients (13.2%) received neoadjuvant chemotherapy followed by gemcitabine-based chemoradiation (TX3), 68 patients (40.7%) received neoadjuvant chemotherapy followed by fluoropyrimidine based chemoradiation (TX4), and 18 patients (10.8%) received neoadjuvant chemotherapy alone (TX5). In patients who received neoadjuvant chemotherapy only (TX5), two patients (1.2%) received fluoropyrimidine based chemotherapy and 16 patients (9.6%) received gemcitabine-based chemotherapy. After completion of neoadjuvant therapy, all patients were re-evaluated by pancreatic protocol computed tomography (CT) scan and PD was performed only in selected patients who had no disease progression or metastasis, and had no contraindications to major abdominal surgery.
Following PD, patients were evaluated every 6 months by physical examination, chest radiography, abdominal CT scan or positron emission tomography (PET) scan. The development of a new low-density mass or intra-abdominal lymphadenopathy in the regions of the resected pancreas or mesenteric root was considered a locoregional relapse or recurrence. Any low-density masses in the liver or lungs or distant sites were considered distant metastasis.
Lee S.M., Katz M.H., Liu L., Sundar M., Wang H., Varadhachary G.R., Wolff R.A., Lee J.E., Maitra A., Fleming J.B., Rashid A, & Wang H. (2016). Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma after Neoadjuvant Therapy as a Prognostic Indicator for Survival. The American journal of surgical pathology, 40(12), 1653-1660.
Publication 2016
Abdomen Abdominal Cavity Adenocarcinoma Anophthalmia with pulmonary hypoplasia Bile Chemoradiotherapy Disease Progression Duct, Bile Ductal Carcinoma Ethics Committees, Research Gemcitabine Liver Lung Lymphadenopathy Males Malignant Neoplasms Mesentery Neoadjuvant Chemoradiotherapy Neoadjuvant Chemotherapy Neoadjuvant Therapy Neoplasm Metastasis Neoplasms, Mucinous Pancreas Pancreatectomy Pancreatic Neoplasm Papillary Adenocarcinoma Patients Pharmacotherapy Physical Examination Positron-Emission Tomography Radiography, Thoracic Radionuclide Imaging Recurrence Relapse Tooth Root Woman X-Ray Computed Tomography
5
Colorectal Cancer Care in Taiwan's NHI
Cited 3 times
Since March 1995, the Taiwan Department of Health has integrated 13 health insurance plans into a universal insurance program. This compulsory social insurance program covers approximately 99% of the residents of Taiwan and has contracts with 97% of medical providers.17 –19 (link) Taiwan's National Health Insurance (NHI) has the unique characteristics of universal insurance coverage and a single-payer system with the government as a sole insurer. Patients have free access to care with any physician or hospital they choose. The insurance premium is calculated by the insurant's individual monthly income reported to the Bureau. The data for this study were collected from Taiwan's NHIRD for the years 20072011.
Our study cohort consisted of Taiwanese patients diagnosed with colorectal cancer from 2007 to 2011. The patients with CRC (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes colon cancer: 153x, rectal cancer: 154x) underwent both surgical resection (45.7x, 45.8, 45.9x, 48.4x, 48.5, 48.6x, 48.74) of colorectal cancer and chemotherapy (oxaliplatin, 5-flurouracil, capecitabine, ufur, or irinotecan) or radiotherapy (92.2x) for their disease during this period. Patients who had chemoradiation both 3 months before surgical resection (neoadjuvant chemoradiation) and 12 months after surgical resection (adjuvant chemoradiation) were included in our study for similar aggressiveness of adjuvant and neoadjuvant treatments. Those patients who received palliative stoma formation (code 46x) only without surgical resection procedures were excluded. A patient selection flow chart is shown in Figure 1.
Wu C.C., Hsu T.W., Chang C.M., Yu C.H, & Lee C.C. (2015). Age-Adjusted Charlson Comorbidity Index Scores as Predictor of Survival in Colorectal Cancer Patients Who Underwent Surgical Resection and Chemoradiation. Medicine, 94(2), e431.
Publication 2015
Cancer of Colon Capecitabine Chemoradiotherapy Chemoradiotherapy, Adjuvant Colorectal Carcinoma Compulsive Behavior Health Insurance Infantile Neuroaxonal Dystrophy Irinotecan Menstruation Disturbances National Health Insurance Neoadjuvant Chemoradiotherapy Neoadjuvant Therapy Operative Surgical Procedures Oxaliplatin Patients Pharmaceutical Adjuvants Pharmacotherapy Physicians Radiotherapy Rectal Cancer Single-Payer System Surgical Stoma

Most recents protocols related to «Neoadjuvant Chemoradiotherapy»

1
Examining Colorectal Cancer Biomarkers
The Cancer Genome Atlas (TCGA) data (TCGA-COAD and TCGA-READ datasets) and NCBI GEO (GSE190826 dataset) were used to examine the expression of SPP1, S100A4 and SPARC and to perform survival analysis in colorectal cancer patients. TCGA data included information about SPP1, S100A4 and SPARC expression, that was evaluated in the following groups of patients: a) with colorectal cancer (common group) (N=417), b) with colon cancer, including transverse colon, ascending colon, descending colon, sigmoid colon, cecum, hepatic flexure, splenic flexure (n=305), c) with rectal cancer, including rectosigmoid junction and rectum (N=112), with available clinical information and records on recurrence and survival rates (in details in Supplementary Table S1). Patients with advanced stage IV were excluded. GSE190826 dataset included 92 patients with rectal cancer treated with neoadjuvant chemoradiotherapy (NCRT); information about pre-treatment levels of SPP1, S100A4 and SPARC mRNA expression was obtained. The TCGA biolinks was used for retrieving RNA-seq data from the GDC database. The raw sequencing reads were processed via the DESeq2 R package. The raw counts were depth normalized and variance stabilized via the variance stabilizing transformation (VST) for downstream survival analysis.
Kazakova E., Rakina M., Sudarskikh T., Iamshchikov P., Tarasova A., Tashireva L., Afanasiev S., Dobrodeev A., Zhuikova L., Cherdyntseva N., Kzhyshkowska J, & Larionova I. (2023). Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancers. Frontiers in Oncology, 13, 1058337.
Publication 2023
Cancer of Colon Cecum Chronic Obstructive Airway Disease Colic Flexure, Right Colon, Ascending Colon, Descending Colorectal Carcinoma Genome Left Colic Flexure Malignant Neoplasms Neoadjuvant Chemoradiotherapy Patients Rectal Cancer Rectum Recurrence RNA, Messenger RNA-Seq Sigmoid Colon SPARC protein, human SPP1 protein, human Transverse Colon
2
Neoadjuvant Short-course Radiotherapy and Delayed Surgery for Rectal Cancer
Between March 2018 and July 2021, 26 patients were treated with the concept of neoadjuvant radiotherapy (5 × 5 Gy) and delayed surgery (SRT-delay) for rectal cancer at Ruppin- Brandenburg University Hospital. All patients had locally advanced primary adenocarcinoma (≥uT3 or/and N+) in the lower or middle third of the rectum. In addition, patients with locally advanced upper third rectal cancer whose main tumor mass appeared caudal to the promontory on sagittal MRI view were included.
Patients were assigned to this form of neoadjuvant therapy because they either could not tolerate conventional neoadjuvant chemoradiation due to their comorbidities or refused chemotherapy.
Short-term neoadjuvant radiotherapy included five fractions of 5 Gy in one week (5 × 5 Gy), followed by an interval of about 8 weeks before surgery.
22 of the 26 patients underwent initial staging (CT, endoscopy, MRI) and complete re-staging before surgery. 4 of 26 patients had to be excluded from the study because of insufficient re-staging. In 2 of these 4 cases, inserted hip arthroplasties caused poor MRI quality. MRI was not possible in one patient, and re-staging endoscopy was not performed in the remaining patient.
The clinical data of the 22 patients enrolled in the study are shown in Table 1.
The study was approved by the ethics committee of the Brandenburg Medical School (No. E-02-20210930).
Tumor downsizing after neoadjuvant therapy was assessed by comparing staging and re-staging data on MRI and endoscopy and by comparing initial staging data with pathological findings.
Albrecht H.C., Wagner S., Sandbrink C, & Gretschel S. (2023). Downsizing of rectal cancer following neoadjuvant radiotherapy (5 × 5 Gy) and long interval surgery evaluated using MRI semiautomated volumetric measurements, a retrospective study. Frontiers in Surgery, 10, 1106177.
Publication 2023
Adenocarcinoma Arthroplasty Endoscopy, Gastrointestinal Ethics Committees Neoadjuvant Chemoradiotherapy Neoadjuvant Radiotherapy Neoadjuvant Therapy Neoplasms Operative Surgical Procedures Patients Pharmacotherapy Rectal Cancer Rectum
3
Transcriptomic Analysis of PDAC and ASCP
This study included paraffin specimens from 29 ASCP patients who underwent a pancreaticoduodenectomy from 2014 to 2019 at the West China Hospital, Sichuan University. As a control, tumor specimens from 54 PDAC patients matched with ASCP cases for sex and age were also chosen. The diagnostic pathology report for specimens of ASCP and PDAC was provided by the Pathology Department, West China Hospital of Sichuan University. Patients with PC who had received neoadjuvant chemoradiotherapy, had other cancers, or were lost during follow-up were excluded from the analysis. PC patients were retrieved from our database to acquire detailed information on treatments, pathological tumor characteristics, surgical treatments, and follow-up. The data were further confirmed by checking against the patients’ medical records. The patient information is shown in Table 1.
Transcriptome profiles of 183 PDAC cases were obtained from The Cancer Genome Atlas (TCGA) [22 (link)]. The clinical data of PDAC patients are presented in Table S1. The Gene Expression Omnibus (GEO) is a public database that provides functional genomic information [23 (link)]. The scRNA-seq data of PDAC and ASCP were obtained from the GEO database, including PDAC samples from GSE111672 [24 (link)] and one ASPC sample from GSE165399 [25 (link)].
Zhang Z., Xiong Q., Xu Y., Cai X., Zhang L, & Zhu Q. (2023). The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma. Journal of Clinical Medicine, 12(4), 1398.
Publication 2023
Anophthalmia with pulmonary hypoplasia Diagnosis Gene Expression Genome Malignant Neoplasms Neoadjuvant Chemoradiotherapy Neoplasms Operative Surgical Procedures Pancreaticoduodenectomy Paraffin Patients Single-Cell RNA-Seq
4
Colorectal Cancer Immunome Analysis
We retrospectively collected 449 CRC patients at two different hospitals as training and validation cohorts. This study was authorized by the ethics committees of Yantai Yuhuangding Hospital (Approval No.2018–118) and Guangzhou Red Cross Hospital (Approval No.2019–227-01) and conformed to the declaration of Helsinki. Informed consent was obtained from all patients for the acquisition and use of clinical data and tumor sections. The training cohort was comprised of 310 patients receiving curative resection at Yantai Yuhuangding Hospital between 2012 and 2015, with a median follow-up duration of 57.5 months. The last follow-up time for the training cohort was August 2019. The validation cohort consisted of 139 patients receiving curative resection at Guangzhou Red Cross Hospital between 2013 and 2015, with a median follow-up duration of 65.0 months. The last follow-up time for the validation cohort was January 2020. The inclusion criteria were as follows: (i) colon cancer or middle-high rectal cancer; (ii) stage II–III disease; (iii) tumor specimens and survival information; (iv) the absence of distant metastasis; and (v) the absence of neoadjuvant chemoradiotherapy. The reason is that neoadjuvant chemoradiotherapy may affect the infiltration of immune cells in tumor tissues.
The microarray datasets (GSE39582 and GSE17536) were downloaded from the Gene Expression Omnibus repository. The levels of gene expression were first normalized by the limma package and further log2-transformed. For these genes with multiple probe sets, those with median levels were used. The batch effects between these two microarray datasets were removed by the RobustRankAggreg package. After removing batch effects, the combined microarray (GSE39582 and GSE17536) was used for calculating the estimated proportion of AMCs using the CIBERSORT algorithm,22 (link) including 571 stage II–III cases with complete clinical and follow-up data. A threshold of p value <0.05 is recommended for further analysis.22 (link) And 82 cases were excluded because of these cases with a p value of ≥0.05. Four hundred and eighty-nine cases with a median follow-up of 53.0 months were finally fitted in the subsequent analysis as the independent cohort.
Li J., Mo Y., Wei Q., Chen J, & Xu G. (2023). High Infiltration of CD203c+ Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer. Journal of Inflammation Research, 16, 723-735.
Publication 2023
Cancer of Colon Ethics Committees, Clinical Gene Expression Inpatient Microarray Analysis Multiple Birth Offspring Neoadjuvant Chemoradiotherapy Neoplasm Metastasis Neoplasms Patients Rectal Cancer Tissues
5
Standardized Perioperative Rectal Cancer Management
Perioperative management was standardized and in agreement with the guidelines of the European Cancer Centre Certification and the ERAS society. Clinical examination, measurement of carcinoembryonic antigen; total colonoscopy; rigid rectoscopy; CT scan of the chest, abdomen and pelvis; and pelvic MRI were performed in all patients. Whenever suspicious liver lesions were seen, a liver MRI was performed. Patients were presented at the weekly interdisciplinary tumor board for digestive cancer following completion of staging. Long-course neoadjuvant chemoradiotherapy (CRT: 50.4 Gy with concurrent capecitabine) was indicated for tumors with ≥cT3 and/or N+ on MRI or tumors with threatened circumferential (≤1 mm) or distal resection margins [27 (link)]. Restaging with pelvic MRI and rigid rectoscopy was performed 6–8 weeks following completion of neoadjuvant CRT. A taTME was performed 8–12 weeks after neoadjuvant CRT. Adjuvant chemotherapy was discussed at the postoperative tumor board and was started 6-8 weeks postoperatively, when indicated. Oncologic surveillance followed international guidelines [27 (link)].
Gloor S., Pozza G., Troller R., Wehrli M, & Adamina M. (2023). Surgical Outcomes, Long-Term Recurrence Rate, and Resource Utilization in a Prospective Cohort of 165 Patients Treated by Transanal Total Mesorectal Excision for Distal Rectal Cancer. Cancers, 15(4), 1190.
Publication 2023
Abdomen Capecitabine CEACAM5 protein, human Chemotherapy, Adjuvant Chest Colonoscopy estrogen receptor alpha, human Europeans Gastrointestinal Cancer Liver Malignant Neoplasms Muscle Rigidity Neoadjuvant Chemoradiotherapy Neoadjuvant Therapy Neoplasms Patients Pelvis Physical Examination Surgical Margins Vision X-Ray Computed Tomography

Top products related to «Neoadjuvant Chemoradiotherapy»

1
Mirneasy ffpe kit by Qiagen
Sourced in Germany, United States, Netherlands, Italy, United Kingdom, Australia, China
The MiRNeasy FFPE Kit is a product designed for the purification of total RNA, including small RNAs, from formalin-fixed, paraffin-embedded (FFPE) tissue samples. It is a tool for researchers to extract and isolate RNA from these types of samples.
2
Hct116 by National Collection of Authenticated Cell Cultures
Sourced in China, United States
HCT116 is a widely used human colorectal carcinoma cell line. It is a commonly employed tool for research in various fields, including cancer biology, drug development, and cellular and molecular studies.
3
Dld 1 by National Collection of Authenticated Cell Cultures
Sourced in China, United States
The DLD-1 is a cell line derived from human colorectal adenocarcinoma. It is a widely used tool for research in cancer biology and drug development.
4
Rnalater by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.
5
Ncm460 by National Collection of Authenticated Cell Cultures
Sourced in China
The NCM460 is a cell line derived from normal human colon mucosa. It is a non-transformed, diploid cell line that maintains many characteristics of normal colon epithelial cells. The NCM460 cell line is commonly used in research related to human colon physiology and pathology.
6
Caco 2 by National Collection of Authenticated Cell Cultures
Sourced in China
Caco-2 is a cell line derived from a human colorectal adenocarcinoma. It is a commonly used in vitro model for studying intestinal permeability and absorption of drugs and other compounds.
7
Sw480 by National Collection of Authenticated Cell Cultures
Sourced in China, United States
The SW480 cell line is a human colorectal adenocarcinoma cell line. It is a well-characterized and widely used model for cancer research.
8
Spss statistics 23 by IBM
Sourced in United States, Germany, Japan, United Kingdom, Belgium, Australia, Austria, Poland, China, Italy
SPSS Statistics 23 is a software package used for statistical analysis. It provides a wide range of statistical and graphical techniques to analyze and visualize data. The core function of SPSS Statistics 23 is to enable users to perform data management, analysis, and presentation tasks.
9
Spss version by IBM
Sourced in United States, United Kingdom, Japan, Germany
SPSS is a software package used for statistical analysis. It provides a graphical user interface and a robust set of tools for data manipulation, analysis, and visualization. SPSS is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, factor analysis, and time series analysis.
10
Spss statistics ver 22 by IBM
Sourced in United States, Japan
SPSS Statistics ver. 22.0 is a software application for statistical analysis. It provides a comprehensive set of tools for data management, analysis, and presentation. The software is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, hypothesis testing, and multivariate analysis.

More about "Neoadjuvant Chemoradiotherapy"

Neoadjuvant chemoradiotherapy, also known as preoperative chemoradiation, is a treatment approach used for certain types of cancers.
It involves the combination of chemotherapy and radiotherapy administered before the primary treatment, typically surgery.
The goal of this approach is to shrink the tumor, improve the chances of successful surgery, and potentially enhance long-term outcomes.
The effectiveness of neoadjuvant chemoradiotherapy protocols can be optimized through data-driven decision making.
Researchers can utilize AI-driven solutions, such as those offered by PubCompare.ai, to quickly locate and compare the latest neoadjuvant chemoradiotherapy protocols from scientific literature, preprints, and patents.
This allows them to identify the most effective treatment strategies and products.
To further enhance their research, researchers may also utilize tools and kits such as the MiRNeasy FFPE Kit for extracting and purifying RNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples.
Cell lines like HCT116, DLD-1, NCM460, Caco-2, and SW480 can be used for in vitro studies.
RNAlater, a RNA stabilization reagent, can be employed to preserve RNA integrity.
Statistical analysis can be performed using SPSS Statistics, with versions such as 23 and 22.0 available.
By incorporating these insights and tools, researchers can experience the power of data-driven decision making and optimize their neoadjuvant chemoradiotherapy research, leading to improved treatment protocols and enhanced patient outcomes.